These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19939923)

  • 1. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
    Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
    J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
    Ooms M; Letko M; Binka M; Simon V
    PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
    Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
    PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
    Ooms M; Letko M; Simon V
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping Region of Human Restriction Factor APOBEC3H Critical for Interaction with HIV-1 Vif.
    Nakashima M; Tsuzuki S; Awazu H; Hamano A; Okada A; Ode H; Maejima M; Hachiya A; Yokomaku Y; Watanabe N; Akari H; Iwatani Y
    J Mol Biol; 2017 Apr; 429(8):1262-1276. PubMed ID: 28336404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
    J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
    Zhen A; Du J; Zhou X; Xiong Y; Yu XF
    PLoS One; 2012; 7(7):e38771. PubMed ID: 22859935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif.
    Zhao K; Du J; Rui Y; Zheng W; Kang J; Hou J; Wang K; Zhang W; Simon VA; Yu XF
    Cell Cycle; 2015; 14(6):838-47. PubMed ID: 25590520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.
    Wang J; Becker JT; Shi K; Lauer KV; Salamango DJ; Aihara H; Shaban NM; Harris RS
    J Mol Biol; 2019 Dec; 431(24):5019-5031. PubMed ID: 31628948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
    Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
    J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection.
    Gourraud PA; Karaouni A; Woo JM; Schmidt T; Oksenberg JR; Hecht FM; Liegler TJ; Barbour JD
    Hum Immunol; 2011 Mar; 72(3):207-12. PubMed ID: 21167246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
    Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
    J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Davis RW; York IA; Zheng YH
    J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.
    Ooms M; Majdak S; Seibert CW; Harari A; Simon V
    J Virol; 2010 Aug; 84(16):7961-9. PubMed ID: 20519396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.